Global Von Willebrand Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Von Willebrand Disease Treatment Market is presumed to reach the market size of nearly USD 1065.41 Million by 2032 from USD 601.92 Million in 2023 with a CAGR of 6.55% under the study period 2024-2032.

Von Willebrand disease (VWD) is caused by a deficiency or dysfunctioning of a protein known as von Willebrand factor (VWF). It is a common genetic hemorrhagic disorder. The role of VWF is to binds with factor VIII(a key clotting protein) and platelets in blood vessel walls, and help form a platelet plug during the clotting process. In Von Willebrand disease the clotting process is delayed and leads to high blood loss in the incidence of injury. There are many treatments available for patients with von Willebrand disease including hormonal and non-hormonal therapies.

MARKET DYNAMICS

The market is growing due to the high prevalence of von Willebrand disease globally. In 2019, the PWD was projected to affect about 1% of the general population; however, clinically significant disease prevalence is predicted to be about 125 per million, with severe disease affecting up to 5 people per million. As per World Federation of Hemophilia's global survey conducted in the year 2017, 76,144 people were affected by von Willebrand disease (vWD) across the world. The rising awareness of von Willebrand disease (VWD) and increasing patient assistance programs are also driving the growth of the market. Von Willebrand disease (VWD) is a rare hereditary that may not be diagnosed and requires awareness in patient assistance programs. Therefore, many organizations and companies are focusing on increasing awareness among people about von Willebrand's disease. For example, the American Society of Hematology (ASH) takes several initiatives such as establishing the clinical research training institute in Latin America, implementing a global research award, and visitor training program, which is expected to boost the market's growth during the forecast period. However, the high cost of treatment is a significant challenge for patients with von Willebrand disease (VWD).

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Von Willebrand Disease Treatment. The growth and trends of Von Willebrand Disease Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Von Willebrand Disease Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

Type 1 Von Willebrand Disease
Type 2 Von Willebrand Disease
Type 3 Von Willebrand Disease
Acquired Von Willebrand Disease

By Drug

Desmopressin
Clotstabilizing Medications
Replacement Therapies
Contraceptives
Others

By Route of Administration

Oral
Injection
Others

By Gender

Men
Women

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Von Willebrand Disease Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Von Willebrand Disease Treatment market include Octapharma AG, Grifols, SA., Shire Plc, Bayer AG, CSL Behring, Pfizer Inc., Ako Inc., Ferring BV. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11215007

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. VON WILLEBRAND DISEASE TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By Drug
- 3.7.3 Market Attractiveness Analysis By Route of Administration
- 3.7.4 Market Attractiveness Analysis By Gender
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DISEASE TYPE

5.1. Overview By Disease Type
5.2. Historical and Forecast Data Analysis By Disease Type
5.3. Type 1 Von Willebrand Disease Historic and Forecast Sales By Regions
5.4. Type 2 Von Willebrand Disease Historic and Forecast Sales By Regions
5.5. Type 3 Von Willebrand Disease Historic and Forecast Sales By Regions
5.6. Acquired Von Willebrand Disease Historic and Forecast Sales By Regions

6. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DRUG

6.1. Overview By Drug
6.2. Historical and Forecast Data Analysis By Drug
6.3. Desmopressin Historic and Forecast Sales By Regions
6.4. Clotstabilizing Medications Historic and Forecast Sales By Regions
6.5. Replacement Therapies Historic and Forecast Sales By Regions
6.6. Contraceptives Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1. Overview By Route of Administration
7.2. Historical and Forecast Data Analysis By Route of Administration
7.3. Oral Historic and Forecast Sales By Regions
7.4. Injection Historic and Forecast Sales By Regions
7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY GENDER

8.1. Overview By Gender
8.2. Historical and Forecast Data Analysis By Gender
8.3. Men Historic and Forecast Sales By Regions
8.4. Women Historic and Forecast Sales By Regions

9. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1. Overview By Distribution Channel
9.2. Historical and Forecast Data Analysis By Distribution Channel
9.3. Hospital Pharmacies Historic and Forecast Sales By Regions
9.4. Retail Pharmacies Historic and Forecast Sales By Regions
9.5. Online Pharmacies Historic and Forecast Sales By Regions

10. GLOBAL VON WILLEBRAND DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE VON WILLEBRAND DISEASE TREATMENT COMPANIES

11.1. Von Willebrand Disease Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF VON WILLEBRAND DISEASE TREATMENT INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Octapharma AG
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Grifols SA.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. Ferring BV
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. Shire Plc
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. Bayer AG
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. CSL Behring
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Pfizer Inc.
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Ako Inc.
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies